Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

18.54
+0.28001.53%
Post-market: 18.850.3100+1.67%17:13 EST
Volume:3.11M
Turnover:57.69M
Market Cap:58.57B
PE:82.50
High:18.79
Open:18.75
Low:18.46
Close:18.26
52wk High:18.79
52wk Low:12.99
Shares:3.16B
Float Shares:3.06B
Volume Ratio:1.19
T/O Rate:0.10%
Dividend:0.64
Dividend Rate:3.45%
EPS(TTM):0.2247
EPS(LYR):0.2245
ROE:1.50%
ROA:2.47%
PB:1.19
PE(LYR):82.59

Loading ...

Takeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline

TIPRANKS
·
6 hours ago

Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors

TIPRANKS
·
6 hours ago

Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study

TIPRANKS
·
6 hours ago

Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live
·
Yesterday

Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy

TIPRANKS
·
Feb 14

Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update

TIPRANKS
·
Feb 14

Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial

TIPRANKS
·
Feb 12

Takeda granted Priority Review for oveporexton by FDA

TIPRANKS
·
Feb 10

Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

Benzinga
·
Feb 10

Takeda Pharmaceutical Invests $1.7 Billion in Iambic to Expand AI-Powered Drug Discovery

Deep News
·
Feb 09

Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors

TIPRANKS
·
Feb 07

Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies

TIPRANKS
·
Feb 07

Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next

TIPRANKS
·
Jan 31

Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control

Benzinga
·
Jan 29

Takeda raises FY25 core EPS view to 486 yen from 479 yen

TIPRANKS
·
Jan 29

Takeda reports Q3 core EPS 428 yen vs. 443 yen last year

TIPRANKS
·
Jan 29

Takeda Pharmaceutical Q3 Adj. EPS $0.47 Misses $0.55 Estimate, Sales $7.600B Miss $8.530B Estimate

Benzinga
·
Jan 29

Press Release: Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE(R) Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

Dow Jones
·
Jan 29

Medicare is about to start negotiating the prices of medications administered by doctors

Dow Jones
·
Jan 28

Takeda Expected to Report Sharply Higher Third-Quarter Net Profit -- Earnings Preview

Dow Jones
·
Jan 28